Abstract: IL-23/Th17 axis has been found to play a central role in the  pathogenesis of psoriasis. Biological agents, such as TNF-α inhibitors, IL-12/23 antagonists, IL-17 antagonists, which are directly or indirectly targeted to this pathway, are impressive in the treatment of moderate to severe psoriasis. Pharmacogenetics can predict drug efficacy between different individuals by studying the association of drug efficacy. The pharmacogenetic research and application of biological agents can make the treatment of psoriasis more reasonable and individualized. The update on pharmacogenetics of biological agents in the treatment of psoriasis is reviewed in this paper.

Key words: psoriasis, biological agents, pharmacogenetics